
Opinion|Videos|June 5, 2025
Recent Advances in First-Line Combination Therapy for EGFR-mutated Metastatic NSCLC: Exploring Amivantamab + Lazertinib and Osimertinib-Based Regimens
Author(s)Rachel E. Sanborn, MD
An expert discusses recent updates on first-line treatments in EGFR-mutated NSCLC, including the MARIPOSA trial comparing amivantamab + lazertinib vs osimertinib, and the FLAURA2 trial of osimertinib + chemotherapy, and how the data is likely to impact the treatment landscape.
Advertisement
Episodes in this series

Please discuss recent updates on first-line (1L) treatments in EGFR-mutated NSCLC.
How do you see recent data impacting the treatment landscape?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















